2025 International Congress

October 5-9, 2025. Honolulu, Hawaii.

View by Title View Categories

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

A randomised controlled feasibility study of a technology-assisted home-based aerobic exercise program for individuals with Parkinson’s disease

S. Neo, Z. Yee, W. Li, HL. Ng, R. Hoe, C. Chung (Singapore, Singapore)
A Randomized Clinical Trial of Immersive Virtual Reality and Cognitive Rehabilitation for Mild Cognitive Impairment in Parkinson’s Disease

A. Puig-Davi, A. Moreu-Valls, S. Martinez-Horta, G. Kulisevsky, J. Rodriguez-Antiguedad, A. Horta-Barba, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)
A Randomized, Double-blind Phase 3 Trial of Amlenetug Versus Placebo in Patients with MSA: The MASCOT Trial

L. Kjærsgaard, M. Nørbæk Jørgensen, S. Zanigni, J. Wiedemann, J. Luthman (Valby, Denmark)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the NLRP3 Inhibitor Vent-02 in Patients with Mild to Moderate Parkinson’s Disease

A. Matta, X. Valencia, K. Pike, L. Warner, O. Spiegelstein, M. Bigal (Waltham, USA)
A rapidly progressive multiple system atrophy-cerebellar variant model presentingα-synuclein oligomer spreading and phosphorylated α-synuclein aggregate formation accompanied with glial inflammation

D. Matsuse, H. Yamaguchi, Y. Nishimura, H. Sekiya, K. Masaki, T. Tanaka, T. Saiga, M. Harada, K. Kira, D. Dickson, K. Fujishima, E. Matsuo, K. Tanaka, R. Yamasaki, N. Isobe, J. Kira (Fukuoka, Japan)
A Rare Case of Anti-Hu Opsoclonus-Myoclonus Syndrome after Immune Checkpoint Inhibitor Immunotherapy in a Patient with Small Cell Lung Cancer in Remission

L. Hong, P. Atit, R. Patil, E. Sandberg, A. Makarova (Tampa, USA)
A Rare Case of Dipeptidyl-peptidase-like protein 6 (DPPX) Antibody-Associated Encephalitis

A. Bata, J. Frey (Morgantown, USA)
A Registry for Sleep and Circadian Health Quality in Parkinson’s Disease (ReSCQu-PD)

J. Cohen (Jacksonville, USA)
A Resting-State fMRI Study of Regional Homogeneity about Pain in Parkinson’s Disease

CJ. Mao, JY. Wu, J. Cheng, YJ. Luo, QM. Jiang (Suzhou, China)
A retrospective analysis of an FMD IDC: considerations that impact outcomes.

D. Del Papa, T. Najafi, J. Harris, T. Peabody, Y. Villalobos, K. Mcinerney, J. Wohn, M. Feldman, J. Margolesky (Miami, USA)

« Previous Page
1
…
5
6
7
8
9
…
181
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z